Mattapan Site Will Contain 105 Affordable Housing Units
Why this matters
Office continues to trade in two distinct markets: trophy assets in walkable submarkets that are leasing at or near record rents, and commodity Class B and C buildings where the basis is still resetting. Underwriting on the latter has moved toward replacement-cost-minus, with credit underwriting now leaning on tenant covenant and remaining lease term rather than mark-to-market expectations. Boston life sciences absorption has moderated from its 2021-2022 pace, and the market is working through a meaningful Cambridge sublease overhang. Multifamily and trophy office remain durable. For LP-positioned capital, the read-through is that the bifurcation is now a structural feature of the sector, not a cycle to wait out.
Editorial analysis · Real Estate Trail Editorial
On the RET wire
- The 48th Boston story tracked on the wire in October 2026. All Boston coverage →
- Disclosed office deal value tracked in October 2026: $22.9B across 69 reported transactions. All Office coverage →
Computed from Real Estate Trail’s own tracked coverage
Colliers arranged the $8.75 million sale of 1590 Blue Hill Ave., a 1.63-acre site in Boston’s Mattapan neighborhood. A partnership between the Planning Office for Urban Affairs, a nonprofit housing developer affiliate…
External link. Real Estate Trail does not republish source content.
Related coverage — Boston · Office
Boston office tower sells at foreclosure auction amid sharp valuation drop
Boston Office Tower Sells at Foreclosure Auction for $546 Million Discount
Boston Office Tower Sells for $546 Million Discount at Auction
Rockpoint Buys Back Boston Office Tower for $260M
Marcus & Millichap Brokers $5M Sale of Industrial Complex in Medford, Massachusetts
MEDFORD, MASS. — Marcus & Millichap has brokered the $5 million sale of a 19,278-square-foot industrial complex in Medford, a northern suburb of Boston. The property at 93 Mystic Ave. was built in the 1950s and compri…
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory dise…